On June 26, 2023, the Ministry of Food and Drug Safety (MFDS) of South Korea submitted Notification G/TBT/N/KOR/1150 to the WTO, proposing revisions to the Regulations on Licensing and Review of Biological Products, etc. The goal of the revisions is to further strengthen the safety of domestic biological products. As of August 25, 2023, these revisions are in the public consultation phase.

China is the worlds second-largest biological product market, and the export volume of related products has been increasing annually. In 2022 alone, Chinas pharmaceutical exports to South Korea reached $1.257 billion. Currently, South Korea is the top export destination for Chinas Western medicine preparations, making these revisions highly impactful for Chinese exporters. It is recommended that export companies closely monitor the changes in these revisions and adjust their product strategies promptly to avoid unnecessary trade losses in future exports.

(1) Definition of new terms: Definitions for new terms such as live bacterial preparations;
(2) Quality system audit requirements: Established quality audit requirements for Quality by Design (QbD) systems (Articles 4 and 26 of the proposal);
(3) Expansion of Scientific Citation Index scope: Expanded the scope of the Scientific Citation Index recognized for pharmacological and clinical trial data (Article 7 of the proposal);
(4) Improved stability test data submission requirements: Changed the submission requirements for stability test data when modifying manufacturing methods;
(5) Risk Management Plan (RMP) submission procedures: Added mandatory RMP submission procedures for self-injection products approved by MFDS;
(6) RNA and DNA vaccine evaluation standards: Established evaluation standards for RNA and DNA vaccines.